A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain-Reference-Cited by-同舟云学术

A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain

Published:2023-12-25 Issue:2 Volume:24 Page:227-235
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Macía Manuel¹,Díaz-Encarnación Montserrat²,Solans-Laqué Roser³,Mallol Elisenda Pomares⁴,Castells Alejandra García⁴,Escribano Cristina⁵,de Arellano Antonio Ramírez⁶

Affiliation:

1. Nephrology Service, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

2. Nephrology Service, Fundació Puigvert, Barcelona, Spain

3. Internal Medicine Department, Hospital Valle de Hebrón, Barcelona, Spain

4. Market Access, PharmaLex, Barcelona, Spain

5. Medical Department, CSL Vifor, Barcelona, Spain

6. HEOR, CSL Vifor, Zürich, Switzerland

Funder

Vifor Fresenius Medical Care Renal Pharma

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2297790

Reference48 articles.

1. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

2. Epidemiological study of primary systemic vasculitides among adults in Southern Spain and review of the main epidemiological studies;Romero-Gómez C;Clin Exp Rheumatol,2015

3. The epidemiology of the primary systemic vasculitides in northwest Spain: Implications of the Chapel Hill Consensus Conference definitions

4. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides

5. The clinical course of ANCA small-vessel vasculitis on chronic dialysis